Clinicians’ Perspectives of Twice-Weekly Rivastigmine Patches for Alzheimer’s Disease Treatment in Spain: The VIITAL 2S Study
Neurologists and geriatricians consider the twice-weekly rivastigmine patch formulation beneficial for AD treatment in terms of treatment compliance, skin tolerability, satisfaction and comfort for patients and caregivers.
Authors
- Gerard Piñol‐Ripoll (ORCID: https://orcid.org/0000-0002-4495-2113)
Institutions
- Hospital Clínico San Carlos (ES)
- Hospital Universitari de Santa Maria (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Hospital Clínic de Barcelona (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
Publication Details
- Journal
- Patient Preference and Adherence
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ppa.s510634
- Citations
- 1
- Primary Topic
- Chemical synthesis and alkaloids
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Esteve Pharmaceuticals